Antonio  De Fusco

Mr. Antonio De Fusco


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2015 in Scientific Reports
Verified
Journal Article
Open access
FFFrancesco Fazio
Francesco Fazio
LLLuana Lionetto
Luana Lionetto
MCMartina Curto
Martina Curto
LILuisa Iacovelli
Luisa Iacovelli
MCMichele Cavallari
Michele Cavallari
MSMaurizio Simmaco
Maurizio Simmaco
The kynurenine pathway of tryptophan metabolism has been implicated in the pathophysiology of psychiatric disorders, including schizophrenia. We report here that the kynurenine metabolite, xanturenic acid (XA), interacts with and activates mGlu2 and mGlu3 metabotropic glutamate receptors in heterologous expression systems. However, the molecular nature of this interaction is unknown and our data cannot exclude that XA acts primarily on other targets, such as the vesicular glutamate transporter, in the CNS. Systemic administration of XA in mice produced antipsychotic-like effects in the MK-801-induced model of hyperactivity. This effect required the presence of mGlu2 receptors and was abrogated by the preferential mGlu2/3 receptor antagonist, LY341495. Because the mGlu2 receptor is a potential drug target in the treatment of schizophrenia, we decided to measure serum levels of XA and other kynurenine metabolites in patients affected by schizophrenia. Serum XA levels were largely reduced in a large cohort of patients affected by schizophrenia, and, in patients with first-episode schizophrenia, levels remained low after 12 months of antipsychotic medication. As opposed to other kynurenine metabolites, XA levels were also significantly reduced in first-degree relatives of patients affected by schizophrenia. We suggest that lowered serum XA levels might represent a novel trait marker for schizophrenia.

5 November 2019 in Brain
Verified
Journal Article
Closed access
AEAlessandro Esposito
Alessandro Esposito
AFAntonio Falace
Antonio Falace
MWMatias Wagner
Matias Wagner
MGMoran Gal
Moran Gal
DMDavide Mei
Davide Mei
RGRenzo Guerrini
Renzo Guerrini
Esposito et al. identify biallelic loss-of-function mutations in DMXL2, encoding a v-ATPase regulatory protein, in three sibling pairs exhibiting Ohtahara syndrome with a progressive course. Patient-derived fibroblasts and Dmxl2-silenced mouse hippocampal neurons show defective lysosomal function and autophagy, resulting in the latter in impaired neuronal development and synapse formation.

14 November 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ARAnna Rocchi
Anna Rocchi
SSSilvio Sacchetti
Silvio Sacchetti
AAntonio De Fusco
Antonio De Fusco
SGSilvia Giovedi
Silvia Giovedi
BPBarbara Parisi
Barbara Parisi
FBFabio Benfenati
Fabio Benfenati
Synapsin I is a phosphoprotein that coats the cytoplasmic side of synaptic vesicles and regulates their trafficking within nerve terminals. Autoantibodies against Syn I have been described in sera and cerebrospinal fluids of patients with numerous neurological diseases, including limbic encephalitis and clinically isolated syndrome; however, the effects and fate of autoantibodies in neurons are still unexplored. We found that in vitro exposure of primary hippocampal neurons to patient’s autoantibodies to SynI decreased the density of excitatory and inhibitory synapses and impaired both glutamatergic and GABAergic synaptic transmission. These effects were reproduced with a purified SynI antibody and completely absent in SynI knockout neurons. Autoantibodies to SynI are internalized by FcγII/III-mediated endocytosis, interact with endogenous SynI, and promote its sequestration and intracellular aggregation. Neurons exposed to human autoantibodies to SynI display a reduced density of SVs, mimicking the SynI loss-of-function phenotype. Our data indicate that autoantibodies to intracellular antigens such as SynI can reach and inactivate their targets and suggest that an antibody-mediated synaptic dysfunction may contribute to the evolution and progression of autoimmune-mediated neurological diseases positive for SynI autoantibodies.

20 May 2014 in Neuropharmacology
Verified
Journal Article
Closed access
VDV. D'Amore
V. D'Amore
ISInes Santolini
Ines Santolini
RCRoberta Celli
Roberta Celli
LLL. Lionetto
L. Lionetto
AAntonio De Fusco
Antonio De Fusco
RNRichard Teke Ngomba
Richard Teke Ngomba

1 October 2015 in Brain Research Bulletin
Verified
Journal Article
Closed access
Jana Dimitrova TchekalarovaJana Dimitrova Tchekalarova
Jana Dimitrova Tchekalarova
SMSlavianka Moyanova
Slavianka Moyanova
AAntonio De Fusco
Antonio De Fusco
RNRichard Teke Ngomba
Richard Teke Ngomba

Verified
Journal Article
Open access
PDF file
SMSlavianka Moyanova
Slavianka Moyanova
AAntonio De Fusco
Antonio De Fusco
ISInes Santolini
Ines Santolini
RCRoberta Celli
Roberta Celli
DBDomenico Bucci
Domenico Bucci
Jana Dimitrova TchekalarovaJana Dimitrova Tchekalarova
Jana Dimitrova Tchekalarova
Absence epilepsy and depression are comorbid disorders, but the molecular link between the two disorders is unknown. Here, we examined the role of the melatoninergic system in the pathophysiology of spike and wave discharges (SWDs) and depression-like behaviour in the Wistar Albino Glaxo from Rijswijk (WAG/Rij) rat model of absence epilepsy. In WAG/Rij rats, SWD incidence was higher during the dark period of the light-dark cycle, in agreement with previous findings. However, neither pinealectomy nor melatonin administration had any effect on SWD incidence, suggesting that the melatoninergic system was not involved in the pathophysiology of absence-like seizures. Endogenous melatonin levels were lower in the hippocampus of WAG/Rij rats as compared to non-epileptic control rats, and this was associated with higher levels of melatonin receptors in the hippocampus, but not in the thalamus. In line with the reduced melatonin levels, cell density was lower in the hippocampus of WAG/Rij rats and was further reduced by pinealectomy. As expected, WAG/Rij rats showed an increased depression-like behaviour in the sucrose preference and forced swim tests, as compared to non-epileptic controls. Pinealectomy abolished the difference between the two strains of rats by enhancing depression-like behaviour in non-epileptic controls. Melatonin replacement displayed a significant antidepressant-like effect in both WAG/Rij and control rats. These findings suggest that a defect of hippocampal melatoninergic system may be one of the mechanisms underlying the depression-like phenotype in WAG/Rij rats and that activation of melatonin receptors might represent a valuable strategy in the treatment of depression associated with absence epilepsy.